蜜桃传媒app

Dr. Beaulieu spent four years at the National Institute of Mental Health with Dr. Robert M. Post at the Biological Psychiatry Branch. He is now at McGill University as an Associate Professor in the Department of Psychiatry and holds associate membership in the Department of Neurology and Neurosurgery. He is also the Medical Chief of the Mood, Anxiety and Impulsivity Disorders Program and Medical Chief of the Bipolar Disorder Program at the Douglas Mental Health University Institute. A psychiatrist and researcher-clinician, Dr. Beaulieu is interested primarily in bipolar disorders and major depression. He studies neurobiological responses to antidepressant and mood stabilizer treatment and potential new treatments for these disorders. Dr. Beaulieu received peer-reviewed research funding from NARSAD (National Alliance for Research on Schizophrenia and Affective Disorders) in the USA, The Stanley Foundation in the USA, the Canadian Fund for Innovation, FRSQ, and CIHR. He is also a member of the Board of Governors of CANMAT (Canadian Network on Mood and Anxiety Treatment) and one of the Investigators and founding members of the bipolar section of CANMAT. Dr. Beaulieu was a member of the Board of Councillors of ISBD (International Society of Bipolar Disorder) from 2006鈥�2008. In 2004, he was the recipient of the Douglas Utting Prize, which is awarded annually to one person in Canada who has contributed significantly to promoting awareness of depression and/or its research and treatment. In addition, he received the prize of 鈥淢茅decin-clinicien-enseignant鈥� in 2009. This honour, awarded by the Quebec Medical Association, underlines the exceptional commitment of a doctor having a teaching responsibility in one of the faculties of medicine in Quebec.